We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Gilead Sciences Inc | NASDAQ:GILD | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.10 | 0.15% | 66.04 | 65.75 | 65.97 | 4,023 | 13:42:20 |
From Oct 2023 to Apr 2024
By Will Feuer
Gilead Sciences said a Phase 3 trial testing Trodelvy in certain lung cancer patients failed to improve overall survival, results that sent shares sharply lower.
Gilead agreed in 2022 to buy Trodelvy-maker Immunomedics for $21 billion.
In the Phase 3 trial, Gilead is evaluating Trodelvy versus docetaxel in patients with metastatic or advanced non-small cell lung cancer that had progressed on or after chemotherapy and checkpoint inhibitor therapy.
Gilead said it did observe a numerical improvement in overall survival favoring Trodelvy, but that the results didn't meet the threshold of the primary endpoint.
Gilead said it plans to discuss the trial results with regulators, and present the data at an upcoming medical meeting.
Write to Will Feuer at Will.Feuer@wsj.com
(END) Dow Jones Newswires
January 22, 2024 09:02 ET (14:02 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
1 Year Gilead Sciences Chart |
1 Month Gilead Sciences Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
